

Approved for use through 09/30/2007. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

**Substitute for form 1449/PTO**

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

*(Use as many sheets as necessary)*

Sheet 1 of 3

Complete If Known	
Application Number	10/712,795
Filing Date	11/13/2003
First Named Inventor	Rosanne M. Crooke
Art Unit	1633
Examiner Name	Janet L. Epps-Ford
Attorney Docket Number	DOC-0216US

## **U.S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

Examiner Signature	/Janet Epps Ford/	Date Considered	07/19/2007
-----------------------	-------------------	--------------------	------------

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 2

**Complete If Known**

Application Number	10/712,795
Filing Date	11/13/2003
First Named Inventor	Rosanne M. Crooke
Art Unit	1633
Examiner Name	Janet L. Epps-Ford
Attorney Docket Number	DOC-0216US

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/JE/	DK	AGRAWAL, S. et al., "Antisense therapeutics: is it as simple as complementary base recognition?" <i>Mol. Med. Today</i> (2000) 6:72-81.	
	DL	CROOKE, S. T., "Basic Principles of Antisense Therapeutics," <i>Antisense Research and Application</i> (1998) Springer-Verlag Press, Berlin, pp 1-50.	
	DM	EMBL Accession No. L27195, January 6, 1994.	
	DN	GRAHAM, M. J. et al., "Inhibition of ApoB-100 as a Therapeutic Strategy for the Treatment of Hyperlipidemias," <i>AHA Abstracts</i> (2002).	
	DO	HUANG, L.-S. et al., "Hypobetalipoproteinemia Due to an Apolipoprotein B Gene Exon 21 Deletion Derived by Alu-Alu Recombination," <i>J. Biol. Chem.</i> (1969) 264(19):11394-11400.	
	DP	JEN, K.-Y. et al., "Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies," <i>Stem Cells</i> (2000) 18:307-319.	
	DQ	LATORRA, D. et al., "Enhanced Allele-Specific PCR Discrimination in SNP Genotyping Using 3' Locked Nucleic Acid (LNA) Primers," <i>Hum. Mutat.</i> (2003) 22:79-85.	
	DR	MA, D. D. F. et al., "Synthetic oligonucleotides as therapeutics: the coming of age," <i>Biotech. Ann. Rev.</i> (2000) 5:155-196.	
	DS	NOWAK-GÖTTL, U. et al., "Lipoprotein (a): Its Role in Childhood Thromboembolism," <i>Pediatrics</i> (1997) 99(6):1-3.	
	DT	ROSSI, J. J. et al., "Introductory Remarks on the General Application of Antisense RNAs and Ribozymes," <i>Methods Enzym.</i> (1993) 5:1-5.	
	DU	SKRAPARI, L. et al., "Glibenclamide improves postprandial hypertriglyceridaemia in Type 2 diabetic patients by reducing chylomicrons but not the very low-density lipoprotein subfraction levels," <i>Diabetic Med.</i> (2001) 18:781-785.	
/JE/	DV	TANAKA, M et al. "Regulation of Apolipoprotein B Production and Secretion in Response to the Change of Intracellular Cholesterol Ester Contents in Rabbit Hepatocytes," <i>J. Biol. Chem.</i> (1993) 268(17):12713-12718.	

Examiner Signature	/Janet Epps Ford/	Date Considered	07/19/2007
--------------------	-------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.